(Spoiler: We shouldn't)
After 8 years in the pharmaceutical industry at Bayer, I've witnessed many supply chain discussions. But the latest data from Handelsblatt should make every industry professional sit up and reach for something stronger than their morning coffee.
The Uncomfortable Truth
80% of active pharmaceutical ingredients (APIs) used in Europe now come from China and India.
Let that sink in for a moment. Eight. Zero. Percent.
David Seignolle, CEO of EuroAPI (Europe's largest API manufacturer), put it bluntly: "The pharmaceutical industry in Europe is at a critical point. It's time to act, or it might be too late."
Déjà Vu: The Chip Crisis Playbook
Remember the Nexperia semiconductor crisis that crippled German automotive production?
We're looking at the same movie, different industry: Semiconductors vs. Pharmaceuticals:
o Same plot: Strategic dependency on concentrated Asian suppliers
o Same risk: Geopolitical leverage and supply disruption
o Same wake-up call: Too late to prevent, hopefully not too late to fix
As Jasmina Kirchhoff from the Institut der deutschen Wirtschaft notes: "Whether chips or antibiotics – the dependencies follow the same structural logic."
The Numbers That Should Concern Us
Let's break down the scale of vulnerability:
o 30% of supply-critical APIs could become scarce if China halts exports
o 500+ medications currently face supply problems in Germany (per BfArM)
o 70%+ of three specific APIs for the German market come solely from China
o 50% of raw materials at EuroAPI's Frankfurt facility are sourced from Asia
Why Did We End Up Here?
The perfect storm of economic rationality meeting strategic myopia:
o Cost pressure: Asian production is significantly cheaper
o Regulatory arbitrage: Stricter environmental regulations in Europe make production more complex and expensive
o Healthcare budget constraints: European health systems operate on tight margins, creating constant downward price pressure
o Short-term thinking: Decades of viewing China as a "cheap workshop" without considering long-term strategic risks
Case in point: EuroAPI has already discontinued 13 APIs from its portfolio. Even Metamizol (a common pain and fever medication) is no longer produced in Europe – too expensive compared to Asian alternatives.
The Generic Drug Dilemma
The problem hits generic manufacturers and API producers hardest:
o Low-margin products (not the lucrative innovative drugs) are most affected
o Antibiotic precursors come almost entirely from Chinese production
o European manufacturers literally cannot compete on price
o Result: Empty pharmacy shelves and growing supply gaps
As Seignolle admits candidly: "Our products are simply too expensive for many generic manufacturers."
Is There a Way Out?
The good news: Europe is finally waking up.
The EU's Critical Medicines Act represents a policy shift toward:
o Location-based incentives for European production
o Stricter supply chain security requirements
o Strategic stockpiling of critical medications
The reality check: The draft was submitted early 2025 but isn't yet implemented. And as Matthias Kromayer from MIG Capital warns, transferring API production back to Europe is possible but would take years.
The Trillion-Dollar Question
How do we balance three competing priorities?
o Healthcare affordability (tight public health budgets)
o Supply security (strategic autonomy)
o Competitive pricing (market economics)
As IW expert Kirchhoff puts it: "The whole thing is constrained by the tight financial margins of healthcare systems. We need to operate more efficiently with existing money – the question is: how?"
The Path Forward: No Easy Answers
What won't work:
o Pure protectionism (Europe still lacks complete production capacity)
o Cosmetic solutions (companies doing "last 2-3 production steps" in Europe while importing everything else from Asia)
o Ignoring the problem until the next crisis
What might work:
o Targeted funding for genuine European API production
o Clear origin requirements in public procurement
o Risk-based approach: not all medications need European production, but critical ones do
o Long-term contracts that acknowledge higher European production costs
o Building resilience through diversification (not complete reshoring)
My Take After 13 Years in This Business
We've spent two decades optimizing for cost while completely discounting geopolitical risk. That bill is now coming due.
The pharmaceutical industry prides itself on innovation and patient safety. Yet we've built a system where a single government's export decision could leave European patients without antibiotics, pain medication, or diabetes treatments.
The Critical Medicines Act is a start, but we need to move from policy documents to production facilities. And fast.
Because unlike with semiconductors, when pharmaceutical supply chains break, people don't just lose their cars – they lose access to life-saving medications.
Questions for My Network
How is your organization addressing API supply chain risks?
Have you seen concrete steps beyond risk assessments?
What's your view on the cost vs. security trade-off?
Can Europe realistically rebuild pharmaceutical production capacity, or is managed dependency the only pragmatic path?
Let's discuss in the comments. This affects all of us – whether you're in manufacturing, regulatory affairs, commercial, or talent acquisition.
Sources: Handelsblatt article "Abhängig von Arznei aus China – Europas nächster Nexperia-Moment?" (November 3, 2025), interviews with David Seignolle (EuroAPI CEO), EU Commissioner Oliver Varhelyi, and industry analysts.
#Pharmaceuticals #SupplyChain #StrategicAutonomy #HealthcareSecurity #ChinaRelations #APIManufacturing
Ready to take control of your pharma career?
Book a free getting to know call. I will tell you honestly where you stand, what the market looks like for your profile, and what your next move should be.
Book a Free Getting to Know Call